Rencontre GFPC-GECP (groupe espagnol) à Paris les jeudi 15 et vendredi 16 mai 2014

 Publications GECP/GFPC :

•  Oncotarget. 2013 Oct;4(10):1572-81.The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.Bonanno L¹, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

• L Bonanno, C Costa, M Majem, JJ Sanchez, I Rodriguez, A Gimenez-Capitan, M Molina-Vila, A Vergnenegre, B Massuti, A Favaretto, M Rugge, C Pallares, M Taron, R RosellCombinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.Molecular Cancer 2014; sous presse (IF 5,13)
• Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.

  Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

  Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.